Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Morphine-6-glucuronide - PAION

Drug Profile

Morphine-6-glucuronide - PAION

Alternative Names: CEE 04410; M6G

Latest Information Update: 01 Jun 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CeNeS Pharmaceuticals
  • Developer PAION; Yichang Humanwell Pharmaceutical
  • Class Morphine derivatives; Opioid analgesics
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase Unknown Postoperative pain

Most Recent Events

  • 05 Nov 2014 Morphine-6-glucuronide licensed to Yichang Humanwell Pharmaceutical in China
  • 03 Nov 2008 Adverse events data from a Meta-analysis of Phase-II and Phase-III trials in Postoperative pain released by PAION
  • 24 Jun 2008 CeNeS has been acquired by PAION
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top